Customs Seize Rogue Drug Shipment as ‘Pharmaceutical Mafia’ Row Erupts

Airfreight shipments of critical bowel disease medication remain blocked at Mauritian customs after an importer bypassed official channels to plug a private-sector shortage, triggering a fierce national debate over parallel importing laws.

The Ministry of Health has firmly refused to clear the cargo, citing strict regulations that require every medicine or active pharmaceutical ingredient (API) to be registered and approved by the Pharmacy Board before import.

Authorities blocked the pharmaceutical shipments due to unresolved doubts regarding the product’s origin.

The crisis erupted following a severe shortage of Mesalazine—a drug used to treat ulcerative colitis—within the private sector.

The official local representative, who holds exclusive distribution rights in Mauritius for the foreign manufacturer, has faced major supply delays blamed on the ongoing conflict in the Middle East.

To mitigate the backlog, the official supplier is shifting its upcoming shipment from sea freight to air cargo, with arrival expected later this week.

Public Sector Unaffected

In stark contrast to the private market, Mauritius’s public healthcare sector has escaped the shortage entirely. The state healthcare system caters to 80% of Mesalazine patients on the island.

According to a Ministry of Health source, the drug remains fully available across all regional hospitals, alongside an alternative substitute molecule, Salazopyrine.

Officials confirmed there has been no deterioration in patient health, noting that treatments remain accessible for those suffering from Crohn’s disease and ulcerative colitis—an illness predominantly affecting the Asian community.

Accusations of a ‘Mafia’ System

The blockaded importer has fiercely hit back at the regulatory standstill, denouncing the current exclusivity system.

“There is no law that can prevent another supplier from importing medicines,” the importer argued, pointing to a training session for pharmacists held on Saturday 16 May.

They claimed the Pharmacy Act states that medicine importation is “open to all licensed pharmacists and wholesalers.”

Going further, the importer attacked the current landscape as an institutional monopoly:

“It is a mafia operating to prevent other suppliers from importing the same pharmaceutical products.”

The importer called for immediate government intervention to standardise quality checks across all imports rather than targeting parallel shipments exclusively, questioning whether the state possesses the genuine political will to regulate parallel importing.

Calls for Patient-Centric Reform

The small and medium pharmaceutical importers’ association (SMEPIA) has backed calls for reform.

Association president Siddique Khodabocus argued that the Pharmacy Board’s duties should extend beyond protecting licensed monopolists to actively ensuring market availability.

“If an agency is unable to bring in a product, the Pharmacy Board should be able to authorise another supplier to source the product from another manufacturing country or supply chain,” Khodabocus said.

He insisted the board must not act merely as a “guardian” for authorised monopolists when patient welfare is at stake.

Government Stands Firm on Safety

The Ministry of Health has maintained an uncompromising stance, declaring that patient safety and product traceability remain its absolute priorities.

Government officials stated that parallel imports require a strict regulatory framework and formal clearance to guarantee authenticity.

The ministry further noted that the blockaded importer could have legally brought in a generic alternative to Mesalazine instead of executing an unauthorised parallel import of a brand already registered by the exclusive local agent.

Under an established solidarity mechanism, private patients unable to find medication can purchase it at cost price from the Ministry of Health’s pharmacy department in Ébène, provided stocks are sufficient.

However, the ministry confirmed that these emergency provisions are not issued free of charge.

The contested cargo will remain impounded at customs until the importer fully regularises their paperwork with the Pharmacy Board.

Medical Background: Chronic Intestinal Illnesses

Ulcerative colitis and Crohn’s disease are chronic, idiopathic inflammatory bowel diseases (IBD) characterized by chronic intestinal tract inflammation. While sharing overlapping clinical features, they remain distinct pathologies.

The exact pathogenesis is only partially understood, though medical consensus links the conditions to genetic predispositions and environmental triggers, including altered intraluminal bacterial flora and increased intestinal permeability.

These factors disrupt intestinal immunity, causing gastrointestinal lesions, severe abdominal pain, fatigue, and potentially bloody diarrhoea.

Chronic cases are managed using anti-inflammatory drugs, immunosuppressors, or biological therapies to induce remission.

Source: Defi Media